These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3404 related items for PubMed ID: 31902326

  • 1. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V, Elharram M, Moura CS, Abrahamowicz M, Bernatsky S, Behlouli H, Pilote L.
    J Am Heart Assoc; 2020 Jan 07; 9(1):e012940. PubMed ID: 31902326
    [Abstract] [Full Text] [Related]

  • 2. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D, Christiansen MN, Mogensen UM, Bundgaard JS, Rørth R, Madelaire C, Fosbøl EL, Schou M, Torp-Pedersen C, Gislason G, Køber L, Kristensen SL.
    Cardiovasc Diabetol; 2020 Jul 06; 19(1):107. PubMed ID: 32631337
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
    Li CX, Liang S, Gao L, Liu H.
    PLoS One; 2021 Jul 06; 16(2):e0244689. PubMed ID: 33606705
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.
    Yang CT, Yang CY, Ou HT, Kuo S.
    Cardiovasc Diabetol; 2020 Jun 13; 19(1):83. PubMed ID: 32534570
    [Abstract] [Full Text] [Related]

  • 7. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
    Ikonomidis I, Pavlidis G, Thymis J, Birba D, Kalogeris A, Kousathana F, Kountouri A, Balampanis K, Parissis J, Andreadou I, Katogiannis K, Dimitriadis G, Bamias A, Iliodromitis E, Lambadiari V.
    J Am Heart Assoc; 2020 May 05; 9(9):e015716. PubMed ID: 32326806
    [Abstract] [Full Text] [Related]

  • 8. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression.
    Maiorino MI, Longo M, Scappaticcio L, Bellastella G, Chiodini P, Esposito K, Giugliano D.
    Cardiovasc Diabetol; 2021 Oct 18; 20(1):210. PubMed ID: 34663316
    [Abstract] [Full Text] [Related]

  • 9. Influence of early use of sodium-glucose transport protein 2 inhibitors, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on the legacy effect of hyperglycemia.
    Deng S, Zhao H, Chai S, Sun Y, Shen P, Lin H, Zhan S.
    Front Endocrinol (Lausanne); 2024 Oct 18; 15():1369908. PubMed ID: 38803473
    [Abstract] [Full Text] [Related]

  • 10. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
    Alfayez OM, Al Yami MS, Alshibani M, Fallatah SB, Al Khushaym NM, Alsheikh R, Alkhatib N.
    Prim Care Diabetes; 2019 Jun 18; 13(3):204-211. PubMed ID: 30713085
    [Abstract] [Full Text] [Related]

  • 11. Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes.
    O'Brien MJ, Karam SL, Wallia A, Kang RH, Cooper AJ, Lancki N, Moran MR, Liss DT, Prospect TA, Ackermann RT.
    JAMA Netw Open; 2018 Dec 07; 1(8):e186125. PubMed ID: 30646315
    [Abstract] [Full Text] [Related]

  • 12. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT, Chang KC, Li CY, Wu JS.
    Cardiovasc Diabetol; 2016 Mar 01; 15():41. PubMed ID: 26932742
    [Abstract] [Full Text] [Related]

  • 13. Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status.
    Bea S, Jeong HE, Filion KB, Yu OH, Cho YM, Lee BH, Chang Y, Byrne CD, Shin JY.
    JAMA Netw Open; 2023 Dec 01; 6(12):e2349856. PubMed ID: 38153732
    [Abstract] [Full Text] [Related]

  • 14. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs.
    Giugliano D, Longo M, Signoriello S, Maiorino MI, Solerte B, Chiodini P, Esposito K.
    Cardiovasc Diabetol; 2022 Mar 16; 21(1):42. PubMed ID: 35296336
    [Abstract] [Full Text] [Related]

  • 15. Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.
    Kintzoglanakis K, Diamantis C, Mariolis A, Paschou SA.
    Diab Vasc Dis Res; 2024 Mar 16; 21(4):14791641241269743. PubMed ID: 39139128
    [Abstract] [Full Text] [Related]

  • 16. [Application of new glucose lowering drugs: DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors].
    Verburg AFE, van den Donk M, Wiersma T.
    Ned Tijdschr Geneeskd; 2019 Jan 14; 163():. PubMed ID: 30676706
    [Abstract] [Full Text] [Related]

  • 17. Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus.
    Nargesi AA, Jeyashanmugaraja GP, Desai N, Lipska K, Krumholz H, Khera R.
    J Am Heart Assoc; 2021 Jul 06; 10(13):e021084. PubMed ID: 33998258
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study.
    Baviera M, Foresta A, Colacioppo P, Macaluso G, Roncaglioni MC, Tettamanti M, Fortino I, Genovese S, Caruso I, Giorgino F.
    Cardiovasc Diabetol; 2022 Aug 24; 21(1):162. PubMed ID: 35999556
    [Abstract] [Full Text] [Related]

  • 19. Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study.
    Sohn M, Dietrich JW, Nauck MA, Lim S.
    Cardiovasc Diabetol; 2023 Jun 28; 22(1):153. PubMed ID: 37381019
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis.
    Fei Y, Tsoi MF, Cheung BMY.
    Cardiovasc Diabetol; 2019 Aug 28; 18(1):112. PubMed ID: 31462224
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 171.